Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03010527 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
A Phase 2 study of Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 2
- Development phase
- 217
- Enrollment target
- 20
- Study locations
NCT03010527 is a Phase 2 study of Chronic Plaque Psoriasis that has completed, run by UCB Biopharma SRL. The registered enrollment target is 217 participants, below the 1,096-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT03010527, a Phase 2 study of Chronic Plaque Psoriasis, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 217 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Bimekizumab
Study Locations (20)
Other
- Ps0011 209 - Edmonton
- Ps0011 201 - North Bay
- Ps0011 206 - Peterborough
- Ps0011 214 - Québec
- Ps0011 203 - Surrey
- Ps0011 205 - Waterloo
- Ps0011 300 - Ostrava
- Ps0011 303 - Pardubice
- Ps0011 301 - Prague
- Ps0011 304 - Prague
- Ps0011 404 - Kecskemét
- Ps0011 400 - Orosháza
Texas
- Ps0011 733 - Dallas
- Ps0011 709 - Houston
- Ps0011 702 - Houston
California
- Ps0011 708 - Los Angeles
District of Columbia
- Ps0011 706 - Washington D.C.
Iowa
- Ps0011 704 - West Des Moines
North Carolina
- Ps0011 738 - Wilmington
Oregon
- Ps0011 712 - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2016-12-14 |
| Est. Completion | 2018-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03010527
The ClinicalTrials.gov registry entry for NCT03010527 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,096-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (80% lower). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03010527 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT03010527 about?
NCT03010527 is a clinical study titled "A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis". This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
What is the current status of trial NCT03010527?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 217 participants. The study started on 2016-12-14. Estimated completion is 2018-09-25.
What conditions does trial NCT03010527 study?
This clinical trial studies the following conditions: Chronic Plaque Psoriasis.
What interventions are being tested in trial NCT03010527?
The interventions under investigation include: Placebo (OTHER), Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT03010527?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03010527 being conducted?
This trial has 20 study locations across California, District of Columbia, Iowa, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
COMPLETED · Phase 4
-
Chronic Plaque Psoriasis (Ps) Registry
COMPLETED
-
Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 4
-
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.